Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This prospective parallel, double-blind, four-arm randomised controlled clinical study is planned to assess the difference in the level of the inflammatory biomarkers expressed following the placement of the first dental implant in patients with history of periodontitis (successfully treated) and healthy controls without the disease, during implant osseointegration period. The subjects in both groups will also be randomised to receive one of the two types of implants provided which have different surface treatment.
This is a prospective, parallel, double-blind, four-arm randomised clinical control study, aims to investigate the changes of clinical parameters and pro-inflammatory biomarkers expression and the shift following the first dental implant placement in patients who have been successfully treated for periodontitis, compared with healthy control without the disease.
The main questions to answer are:
Clinical measurement, GCF and PISF will be collected around the single implant and adjacent teeth, at the following stages (time-point):
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group T-A | Experimental | 7 patients with history of periodontitis |
|
| Group T-B | Experimental | 7 patients with history of periodontitis |
|
| Group C-A | Active Comparator | 7 patients without history of periodontitis |
|
| Group C-B | Active Comparator | 8 patients without history of periodontitis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Megagen implant placement | Other | Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface |
|
| Measure | Description | Time Frame |
|---|---|---|
| Level of matrix metalloproteinase (MMP)-8 expressed in the gingival crevicular and peri-implant sulcular fluids during the early-stage of dental implant placement | To measure the absolute quantification of MMP-8 level expressed during the implant osseointegration period in all study groups via ELISA method. | From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) and 3-months after implant crown restoration (final visit- TP4) |
| Measure | Description | Time Frame |
|---|---|---|
| Shift of the microbial composition in the supragingival dental plaque, identified via 16S rRNA next generation sequencing | Identification and comparison of supragingival dental plaque bacteria species/genus and the shift of the bacterial composition during the early-stage of dental implant placement between study groups | From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4) |
Not provided
Inclusion Criteria:
Specific inclusion criteria for test group:
Specific inclusion criteria for control group:
General inclusion criteria:
Exclusion Criteria:
Female and male
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Norul H Mohamad-Hassan, DDS,MCD | University of Malaya | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Dentistry, University of Malaya | Kuala Lumpur | Kuala Lumpur | 50603 | Malaysia |
Individual participant data that underlie the results reported in this article after deidentification. Researchers should provide a methodologically sound proposal and directed to the principal investigator by email.
Not provided
Beginning 3 months and ending 5 years following article(s) publication.
To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D010518 | Periodontitis |
| D057873 | Peri-Implantitis |
| D003773 | Dental Plaque |
| ID | Term |
|---|---|
| D010510 | Periodontal Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D003741 | Dental Deposits |
Not provided
Not provided
Test group: Patient with history of periodontitis Control group: Patient without history of periodontitis
Patients in both groups will be randomised to receive one of two type of implants with different surface characteristics.
Not provided
Not provided
All participants will be blinded from the randomisation. An opaque envelope will be used to conceal the implant designation and will only be revealed to the operator after the site is ready for implant placement. A blinded researcher will be assigned as clinical assessor who will not be involved with the surgical procedure, subject recruitment nor consent taking. An assistant who is not involved with the research will also be asked to re-code the sample tubes to ensure blinding for data/sample analysis.
| Biomate-Swiss implant | Other | Biomate-Swiss implant with precision dimension laser (PDL) surface |
|
| Shift of proteome profiles in the gingival crevicular and peri-implant sulcular fluids during the early-stage of dental implant placement | To assess the protein profile and levels of expression of the pro-inflammatory cytokines in GCF and gingival tissue via liquid chromatography-electrospray ionization tandem mass spectrometry (LC-MS) proteomic analysis following osseointegration. | From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4) |
| Histological changes in the peri-implant soft tissue before and after implant placement | Number and co-localisation of cells with MMP-8, pro-inflammatory (M1)- and anti-inflammatory (M2)-related cytokines via hematoxylin and eosin staining, immunohistochemistry and immunofluorescence analysis | Between first stage (baseline/pre) and second stage implant surgery (post-operative) at 3 months after the first surgery |
| Changes in the clinical parameters during the early-stage implant placement | To assess intra-oral clinical parameters changes (i.e. patient-level and tooth-level mean periodontal pocket depth (mm) and clinical attachment level (mm); full mouth plaque score (%) and bleeding score (%)) following the first dental implant placement, each time-point (TP). The deeper the depth/higher the level or percentage means the worse the condition is. | From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4) |
| D014076 |
| Tooth Diseases |